Eloxx Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017 - 1997
Net Income	-36.07	-66.73	-34.58	-50.87	-47.19	Upgrade
Depreciation & Amortization	0.7	0.96	0.57	0.56	0.22	Upgrade
Share-Based Compensation	3.02	9.17	8.67	11.34	0	Upgrade
Other Operating Activities	0.5	21.6	-2.83	-0.41	15.6	Upgrade
Operating Cash Flow	-31.85	-35	-28.17	-39.39	-31.37	Upgrade
Capital Expenditures	-0.07	-0.09	0	-0.04	-0.24	Upgrade
Acquisitions	0	2.15	0	0	0	Upgrade
Change in Investments	-	-	-33.75	-100.96	-	Upgrade
Other Investing Activities	-	-	67.54	67.48	-0.08	Upgrade
Investing Cash Flow	-0.07	2.06	33.79	-33.52	-0.32	Upgrade
Common Stock Issued	0	47.72	0	32.88	55.74	Upgrade
Other Financing Activities	8.81	3.07	-3.44	13.92	0.45	Upgrade
Financing Cash Flow	8.81	50.79	-3.44	46.8	56.18	Upgrade
Net Cash Flow	-23.1	17.84	2.19	-26.12	24.5	Upgrade
Free Cash Flow	-31.91	-35.09	-28.17	-39.43	-31.6	Upgrade
Free Cash Flow Per Share	-14.73	-20.06	-28.08	-41.44	-38.97	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.